company background image
SLNC

Silence Therapeutics OTCPK:SLNC.F Stock Report

Last Price

US$6.75

Market Cap

US$606.1m

7D

22.7%

1Y

-25.0%

Updated

19 May, 2022

Data

Company Financials +
SLNC.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SLNC.F Stock Overview

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications.

Silence Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Silence Therapeutics
Historical stock prices
Current Share PriceUS$6.75
52 Week HighUS$46.50
52 Week LowUS$5.00
Beta1.33
1 Month Change3.69%
3 Month Change0.31%
1 Year Change-25.00%
3 Year Change754.43%
5 Year Change525.00%
Change since IPO411.36%

Recent News & Updates

Shareholder Returns

SLNC.FUS BiotechsUS Market
7D22.7%3.6%0.1%
1Y-25.0%-22.1%-12.7%

Return vs Industry: SLNC.F underperformed the US Biotechs industry which returned -21.4% over the past year.

Return vs Market: SLNC.F underperformed the US Market which returned -11.5% over the past year.

Price Volatility

Is SLNC.F's price volatile compared to industry and market?
SLNC.F volatility
SLNC.F Average Weekly Movementn/a
Biotechs Industry Average Movement12.4%
Market Average Movement8.0%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: Insufficient data to determine SLNC.F's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine SLNC.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a105Craig Toomanhttps://www.silence-therapeutics.com

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company’s platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body’s natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell.

Silence Therapeutics Fundamentals Summary

How do Silence Therapeutics's earnings and revenue compare to its market cap?
SLNC.F fundamental statistics
Market CapUK£484.78m
Earnings (TTM)-UK£38.67m
Revenue (TTM)UK£14.99m

32.3x

P/S Ratio

-12.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLNC.F income statement (TTM)
RevenueUK£14.99m
Cost of RevenueUK£8.19m
Gross ProfitUK£6.80m
Other ExpensesUK£45.47m
Earnings-UK£38.67m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.43
Gross Margin45.35%
Net Profit Margin-257.95%
Debt/Equity Ratio0%

How did SLNC.F perform over the long term?

See historical performance and comparison

Valuation

Is Silence Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


121.52x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SLNC.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SLNC.F's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: SLNC.F is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SLNC.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SLNC.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SLNC.F is overvalued based on its PB Ratio (121.5x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is Silence Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-30.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLNC.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLNC.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLNC.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SLNC.F's revenue is expected to decline over the next 3 years (-11.7% per year).

High Growth Revenue: SLNC.F's revenue is forecast to decline over the next 3 years (-11.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SLNC.F's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Silence Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-38.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SLNC.F is currently unprofitable.

Growing Profit Margin: SLNC.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SLNC.F is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.

Accelerating Growth: Unable to compare SLNC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLNC.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: SLNC.F has a negative Return on Equity (-969.27%), as it is currently unprofitable.


Financial Health

How is Silence Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SLNC.F's short term assets (£76.9M) exceed its short term liabilities (£15.7M).

Long Term Liabilities: SLNC.F's short term assets (£76.9M) exceed its long term liabilities (£67.1M).


Debt to Equity History and Analysis

Debt Level: SLNC.F is debt free.

Reducing Debt: SLNC.F has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SLNC.F has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SLNC.F is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 29.7% per year.


Dividend

What is Silence Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SLNC.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLNC.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SLNC.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLNC.F's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SLNC.F has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Craig Tooman (55 yo)

0.25

Tenure

UK£2,479,054

Compensation

Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer & Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N.V. since June 2019. He...


CEO Compensation Analysis

Compensation vs Market: Craig's total compensation ($USD3.10M) is about average for companies of similar size in the US market ($USD3.83M).

Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.


Leadership Team

Experienced Management: SLNC.F's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: SLNC.F's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Silence Therapeutics plc's employee growth, exchange listings and data sources


Key Information

  • Name: Silence Therapeutics plc
  • Ticker: SLNC.F
  • Exchange: OTCPK
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$606.091m
  • Shares outstanding: 89.79m
  • Website: https://www.silence-therapeutics.com

Number of Employees


Location

  • Silence Therapeutics plc
  • 72 Hammersmith Road
  • London
  • Greater London
  • W14 8TH
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.